Current and emerging drugs for acute bacterial skin and skin structure infections: an update. (September 2014)

• Record Type: Journal Article
• Authors: Kollipara, Ramya; Downing, Christopher; Lee, Michael; Guidry, Jacqueline; Curtis, Stephen; Tyring, Stephen
• Is Part Of: Expert opinion on emerging drugs. Volume 19:Number 3(2014:Sep.)
• Page Start: 431
• Page End: 440
• Publication Date: 2014-09
• Subjects: Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1517/14728214.2014.955015
• Languages: English
• ISSNs: 1472-8214

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Antibiotic resistance, the emergence of multidrug-resistant bacteria and the exponential rise of methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) acute bacterial skin and skin structure infections (ABSSSI) pose a great threat to the public health. In order to combat these threats, development of new antibiotics is vital and measures to decrease antibiotic resistance should be prioritized.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This manuscript provides an overview of the current FDA-approved antibiotics and the antibiotics in development for MRSA ABSSSI.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> A great need exists currently for novel antibiotics to combat multidrug-resistant MRSA. As clinicians, it is imperative to implement proper management in order to reduce antibiotic resistance.</p> </abstract>